Joint arthroplasty and infection: Where do we stand?

被引:0
|
作者
Vegari D.N. [1 ]
Parvizi J. [2 ]
机构
[1] Department of Orthopaedic Surgery, Thomas Jefferson University Hospital, Philadelphia, PA 19107
[2] Rothman Institute at Thomas Jefferson University Hospital, Philadelphia
关键词
Antibiotics; Cefazolin; Periprosthetic joint; Skin preparation; Space suits;
D O I
10.1615/JLongTermEffMedImplants.v21.i3.60
中图分类号
学科分类号
摘要
With the field of orthopedic surgery making tremendous advances, no one arena has changed more dramatically then total joint arthroplasty. While this kind of surgery has improved quality of life for many patients, it is not without complications. When they do occur, these complications can be devastating and inflict immense burden on patients and the society. Currently, the rate of periprosthetic joint infection ranges from 0.25% to 2.0%. As the number of total joint arthroplasty procedures is expected to rise considerably, these percentages will impose a financial burden on the field of adult reconstruction. The purpose of our paper is to discuss preventative measures that can be taken to curtail infections, the proper diagnosis of such infections, and the appropriate treatment options. © 2011 by Begell House, Inc.
引用
收藏
页码:225 / 232
页数:7
相关论文
共 50 条
  • [41] WHERE DO WE STAND NOW
    GRIEF, NS
    NATURAL RESOURCES JOURNAL, 1993, 33 (02) : 507 - 521
  • [42] Pegasparaginase: where do we stand?
    Zeidan, Amer
    Wang, Eunice S.
    Wetzler, Meir
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2009, 9 (01) : 111 - 119
  • [43] Response: Where Do We Stand?
    Runnels, Curtis
    JOURNAL OF MEDITERRANEAN ARCHAEOLOGY, 2014, 27 (02): : 272 - 274
  • [44] WHERE DO WE STAND ON MANPOWER
    不详
    VETERINARY RECORD, 1995, 137 (01) : 1 - 1
  • [45] Xenotransplantation, where do we stand?
    Cozzi, E
    Ancona, E
    JOURNAL OF NEPHROLOGY, 2003, 16 : S16 - S21
  • [46] TRIBOLOGY - WHERE DO WE STAND
    CHARLES, T
    ENGINEERING MATERIALS AND DESIGN, 1970, 13 (01): : 47 - &
  • [47] Hyperfractionation: where do we stand?
    Stuschke, M
    Thames, H
    RADIOTHERAPY AND ONCOLOGY, 1998, 46 (02) : 131 - 133
  • [48] WHERE DO WE STAND NOW
    RABINOWITZ, S
    JUDAISM, 1977, 26 (03) : 274 - 278
  • [49] The GSEs: Where Do We Stand?
    Poole, William
    FEDERAL RESERVE BANK OF ST LOUIS REVIEW, 2013, 95 (06): : 601 - 611
  • [50] Toremifene:: where do we stand?
    Mäenpää, J
    Holli, K
    Pasanen, T
    EUROPEAN JOURNAL OF CANCER, 2000, 36 : S61 - S62